Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1847669 | 1.00 | EPHX2 (0.52) | EPHX2TSHRALDH1A1NPSR1POLB | |
| SCHEMBL1847665 | 1.00 | EPHX2 (0.52) | EPHX2TSHRALDH1A1NPSR1POLB | |
| SCHEMBL23815408 | 1.00 | EPHX2 (0.52) | EPHX2TSHRALDH1A1NPSR1POLB | |
| SCHEMBL1847663 | 1.00 | EPHX2 (0.52) | EPHX2TSHRALDH1A1NPSR1POLB | |
| SCHEMBL1398388 | 0.83 | EPHX2 (0.52) | EPHX2TSHRALDH1A1NPSR1POLB | |
| SCHEMBL2719341 | 0.82 | EPHX2 (0.50) | EPHX2TSHRALDH1A1NPSR1POLB | |
| SCHEMBL6495033 | 0.82 | EPHX2 (0.50) | EPHX2TSHRALDH1A1NPSR1POLB | |
| SCHEMBL25041744 | 0.82 | EPHX2 (0.50) | EPHX2TSHRALDH1A1NPSR1POLB | |
| SCHEMBL19557168 | 0.79 | HSD11B1 (0.48) | EPHX2ALDH1A1HSD11B1L3MBTL1KDM4E | |
| SCHEMBL19557166 | 0.79 | HSD11B1 (0.48) | EPHX2ALDH1A1HSD11B1L3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 378 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112876507-A | Trisubstituted olefin tertiary phosphine compound and preparation method thereof | 湖北大学 | 2021-06-01 | — | — | CN | claimed |
| CN-112250709-A | Synthesis method of ortho-aryl substituted tertiary phosphine compound | 湖北大学 | 2021-01-22 | — | — | CN | claimed |
| CN-104926672-A | Method for preparing 4-amino-adamantanecarboxylic acid | SHANGHAI B&C CHEMICAL CO LTD | 2015-09-23 | — | — | CN | claimed |
| US-12590070-B2 | Adamantane derivatives as inhibitors of focal adhesion kinase | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 2026-03-31 | — | — | US | disclosed |
| US-20250325660-A1 | IMMUNOMODULATOR COMPOUNDS AND METHODS OF USE | INCYTE CORP (US) | 2025-10-23 | — | — | US | disclosed |
| CN-120136747-A | Method for preparing adamantane esterified product by utilizing microchannel reactor | 苏州威迈芯材半导体有限公司 | 2025-06-13 | — | — | CN | disclosed |
| US-20250164877-A1 | RADIATION-SENSITIVE COMPOSITION, METHOD FOR FORMING RESIST PATTERN, AND RADIATION-SENSITIVE ACID GENERATOR | JSR CORPORATION (JP) | 2025-05-22 | — | — | US | disclosed |
| EP-4074697-B1 | NOVEL ADAMANTANE DERIVATIVES AS INHIBITORS OF FOCAL ADHESION KINASE | SAMJIN PHARM CO LTD (KR) | 2025-05-21 | — | — | EP | disclosed |
| WO-2025070119-A1 | RADIATION-SENSITIVE COMPOSITION, PATTERN FORMATION METHOD, AND ONIUM SALT COMPOUND | JSR株式会社 | 2025-04-03 | — | — | WO | disclosed |
| WO-2025070125-A1 | RADIATION-SENSITIVE COMPOSITION AND PATTERN FORMATION METHOD | JSR株式会社 | 2025-04-03 | — | — | WO | disclosed |
| US-20250013150-A1 | RADIATION-SENSITIVE COMPOSITION, PATTERN FORMATION METHOD, AND PHOTO-DEGRADABLE BASE | JSR CORPORATION (JP) | 2025-01-09 | — | — | US | disclosed |
| US-5543295-A | ENZYMATICALLY CLEAVABLE; ANALYZING | TROPIX, INC. (US) | 1996-08-06 | — | — | US | disclosed |
| US-5395836-A | Adenosine A1 receptor antagonists | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1995-03-07 | — | — | US | disclosed |
| EP-0619316-A1 | Xanthine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1994-10-12 | — | — | EP | disclosed |
| US-5330900-A | Chemiluminescent 3-(substituted adamant-2'-ylidene) 1,2-dioxetanes | TROPIX, INC. (US) | 1994-07-19 | — | — | US | disclosed |
| US-5326882-A | High speed bioassay | TROPIX, INC. (US) | 1994-07-05 | — | — | US | disclosed |
| US-5220005-A | Reactable with enzyme to release optically detectable energy | TROPIX, INC. (US) | 1993-06-15 | — | — | US | disclosed |
| EP-0497972-A1 | CHEMILUMINESCENT 3-(SUBSTITUTED ADAMANT-2'-YLIDENE) 1,2-DIOXETANES | TROPIX, INC. (US) | 1992-08-12 | — | — | EP | disclosed |
| US-5112960-A | Enzyme cleavable 1,2-dioxetane compound | APPLIED BIOSYSTEMS, LLC | 1992-05-12 | — | — | US | disclosed |
| WO-1992004341-A1 | CHEMILUMINESCENT 3-(SUBSTITUTED ADAMANT-2'-YLIDENE) 1,2-DIOXETANES | TROPIX, INC. (US) | 1992-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250013150-A1 | RADIATION-SENSITIVE COMPOSITION, PATTERN FORMATION METHOD, AND PHOTO-DEGRADABLE BASE | NR2E3, RER1, H1-3 | EPHX2 840/4885TSHR 136/4885ALDH1A1 1767/4885 |
| US-20250325660-A1 | IMMUNOMODULATOR COMPOUNDS AND METHODS OF USE | CD274, PDCD1LG2, PDCD1 | EPHX2 4129/4885TSHR 573/4885ALDH1A1 1759/4885 |
| US-12590070-B2 | Adamantane derivatives as inhibitors of focal adhesion kinase | PTK2, CTTN, ADGRF1 | EPHX2 1409/4885TSHR 1916/4885ALDH1A1 1097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.